BTIG stays Buy rated on NRx Pharmaceuticals, Inc. (NRXP) as FDA waives additional clinical trials
Tweet Send to a Friend
BTIG analyst Thomas Schrader reiterated a Buy rating and $25.00 price target on NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
